1755 ET - Alcon's purchase of a majority of Aurion Biotech, which is developing cell therapies for eye diseases, follows a contentious relationship between the companies. Alcon invested in Aurion in 2022 and sued it last October, and Aurion countersued in November. Alcon opposed Aurion's planned initial public offering. Aurion said it had "rejected multiple inadequate bids" from Alcon. Aurion filed for the IPO confidentially in October and disclosed its plans in January. In the risk factors section of its filing, the company said "We are currently engaged in litigation against our largest stockholder, Alcon." Alcon joined a $120 million Series C financing in 2022 led by Deerfield Management. As of January, other top shareholders included Petrichor and KKR-backed Falcon Vision. (josh.beckerman@wsj.com)
(END) Dow Jones Newswires
March 26, 2025 17:55 ET (21:55 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。